Bryan Laffitte, PhD
Chief Scientific Officer, DTx Pharma
Dr. Laffitte is Chief Scientific Officer for DTx Pharma, a Novartis company. Dr. Laffitte joined DTx Pharma in 2020, bringing twenty years of pharmaceutical and biotechnology industry experience with expertise leading research teams and advancing programs from pre-clinical development through IND filings. Dr. Laffitte was previously Vice President, Biology at Inception Therapeutics where he managed the research activities for Inception and several of its subsidiary companies including Tempest Therapeutics and Lycia Therapeutics. Dr. Laffitte was previously the Director of Regenerative Medicine, Head of Type 1 Diabetes Program and Co-Leader of the Molecular Targeting Initiative at the Genomics Institute of the Novartis Research Foundation and was named Scientist of the Year and VIVA Award winner for 2016 at Novartis. He completed his postdoctoral fellowship at Howard Hughes Medical Institute and earned his PhD from University of California, Los Angeles.